retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Agonism Based Therapies for | Current Cardiovascular Risk Reports Dual and Triple Gut Peptide

Some patients may begin noticing weight loss within the first few weeks, especially when medication is paired with lifestyle changes

Summary Obesity is a chronic progressive disease with increasing prevalence in the United States and around the world

How can GLP-1 therapy help with weight loss

Join WeightWatchers Clinic and get help and advice on weight-loss medication

Gastroparesis (also known as stomach paralysis) is a chronic disease that affects the nerves and muscles in the stomach, interfering with the muscle activity (peristalsis), making stomach muscle contractions slower and weaker, slowing the movement of food through the stomach and small intestine and causing food not to be properly processed or emptied